274 related articles for article (PubMed ID: 30973110)
1. Hybrid Design of Isonicotinic Acid Hydrazide Derivatives: Machine Learning Studies, Synthesis and Biological Evaluation of their Antituberculosis Activity.
Kovalishyn V; Hodyna D; Sinenko VO; Blagodatny V; Semenyuta I; Slivchuk SR; Brovarets V; Poda G; Metelytsia L
Curr Drug Discov Technol; 2020; 17(3):365-375. PubMed ID: 30973110
[TBL] [Abstract][Full Text] [Related]
2. Rational design of isonicotinic acid hydrazide derivatives with antitubercular activity: Machine learning, molecular docking, synthesis and biological testing.
Kovalishyn V; Grouleff J; Semenyuta I; Sinenko VO; Slivchuk SR; Hodyna D; Brovarets V; Blagodatny V; Poda G; Tetko IV; Metelytsia L
Chem Biol Drug Des; 2018 Jul; 92(1):1272-1278. PubMed ID: 29536635
[TBL] [Abstract][Full Text] [Related]
3. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.
Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H
Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383
[TBL] [Abstract][Full Text] [Related]
4. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis.
Eshetie S; Gizachew M; Dagnew M; Kumera G; Woldie H; Ambaw F; Tessema B; Moges F
BMC Infect Dis; 2017 Mar; 17(1):219. PubMed ID: 28320336
[TBL] [Abstract][Full Text] [Related]
6. QSAR Studies, Synthesis and Antibacterial Assessment of New Inhibitors Against Multidrug-Resistant Mycobacterium tuberculosis.
Kovalishyn V; Brovarets V; Blagodatnyi V; Kopernyk I; Hodyna D; Chumachenko S; Shablykin O; Kozachenko O; Vovk M; Barus M; Bratenko M; Metelytsia L
Curr Drug Discov Technol; 2017; 14(1):25-38. PubMed ID: 27829331
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Polyphenolic Profile and Antibacterial Activity of Pomegranate Juice in Combination with Rifampin (R) against MDR-TB Clinical Isolates.
AlMatar M; Var I; Kayar B; Eker E; Kafkas E; Zarifikhosroshahi M; Köksal F
Curr Pharm Biotechnol; 2019; 20(4):317-326. PubMed ID: 30854955
[TBL] [Abstract][Full Text] [Related]
8. Preliminary evaluation of anti-tuberculosis potential of siderophores against drug-resistant Mycobacterium tuberculosis by mycobacteria growth indicator tube-drug sensitivity test.
Gokarn K; Pal RB
BMC Complement Altern Med; 2017 Mar; 17(1):161. PubMed ID: 28327117
[TBL] [Abstract][Full Text] [Related]
9. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.
Mvelase NR; Balakrishna Y; Lutchminarain K; Mlisana K
BMJ Open; 2019 Nov; 9(11):e031663. PubMed ID: 31699736
[TBL] [Abstract][Full Text] [Related]
10. Design of (quinolin-4-ylthio)carboxylic acids as new Escherichia coli DNA gyrase B inhibitors: machine learning studies, molecular docking, synthesis and biological testing.
Metelytsia L; Hodyna D; Dobrodub I; Semenyuta I; Zavhorodnii M; Blagodatny V; Kovalishyn V; Brazhko O
Comput Biol Chem; 2020 Apr; 85():107224. PubMed ID: 32018168
[TBL] [Abstract][Full Text] [Related]
11. The Introduction of Hydrazone, Hydrazide, or Azepane Moieties to the Triterpenoid Core Enhances an Activity Against
Kazakova OB; Medvedeva NI; Smirnova IE; Lopatina TV; Veselovsky AV
Med Chem; 2021; 17(2):134-145. PubMed ID: 31939731
[TBL] [Abstract][Full Text] [Related]
12. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB.
Martins F; Ventura C; Santos S; Viveiros M
Curr Pharm Des; 2014; 20(27):4427-54. PubMed ID: 24245762
[TBL] [Abstract][Full Text] [Related]
13. Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Using the Quantamatrix Multiplexed Assay Platform System.
Wang HY; Uh Y; Kim S; Cho E; Lee JS; Lee H
Ann Lab Med; 2018 Nov; 38(6):569-577. PubMed ID: 30027701
[TBL] [Abstract][Full Text] [Related]
14. Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia.
Khan MY; Kinsara AJ; Osoba AO; Wali S; Samman Y; Memish Z
Int J Antimicrob Agents; 2001 May; 17(5):415-8. PubMed ID: 11337231
[TBL] [Abstract][Full Text] [Related]
15. Naphthoquinones isolated from Diospyros anisandra exhibit potent activity against pan-resistant first-line drugs Mycobacterium tuberculosis strains.
Uc-Cachón AH; Borges-Argáez R; Said-Fernández S; Vargas-Villarreal J; González-Salazar F; Méndez-González M; Cáceres-Farfán M; Molina-Salinas GM
Pulm Pharmacol Ther; 2014 Feb; 27(1):114-20. PubMed ID: 23968826
[TBL] [Abstract][Full Text] [Related]
16. Novel 1-(4-substituted benzylidene)-4-(1-(substituted methyl)-2,3-dioxoindolin-5-yl)semicarbazide derivatives for use against Mycobacterium tuberculosis H37Rv (ATCC 27294) and MDR-TB strain.
Raja S; Prakash CR
Arch Pharm Res; 2013 Apr; 36(4):411-22. PubMed ID: 23440582
[TBL] [Abstract][Full Text] [Related]
17. In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against
Venugopala KN; Tratrat C; Pillay M; Chandrashekharappa S; Al-Attraqchi OHA; Aldhubiab BE; Attimarad M; Alwassil OI; Nair AB; Sreeharsha N; Venugopala R; Morsy MA; Haroun M; Kumalo HM; Odhav B; Mlisana K
Drug Des Devel Ther; 2020; 14():1027-1039. PubMed ID: 32214795
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.
Martins F; Santos S; Ventura C; Elvas-Leitão R; Santos L; Vitorino S; Reis M; Miranda V; Correia HF; Aires-de-Sousa J; Kovalishyn V; Latino DA; Ramos J; Viveiros M
Eur J Med Chem; 2014 Jun; 81():119-38. PubMed ID: 24836065
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Anyplex™ II MTB/MDR kit's performance to rapidly detect isoniazid and rifampicin resistant Mycobacterium tuberculosis from various clinical specimens.
Chumpa N; Kawkitinarong K; Rotcheewaphan S; Sawatpanich A; Petsong S; Tumwasorn S; Suwanpimolkul G
Mol Biol Rep; 2020 Apr; 47(4):2501-2508. PubMed ID: 32124172
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids.
Rodrigues MO; Cantos JB; D'Oca CR; Soares KL; Coelho TS; Piovesan LA; Russowsky D; da Silva PA; D'Oca MG
Bioorg Med Chem; 2013 Nov; 21(22):6910-4. PubMed ID: 24103427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
